Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

Prasugrel monitoring and bleeding in real world patients.

Cayla G, Cuisset T, Silvain J, O'Connor SA, Kerneis M, Castelli C, Quilici J, Bonnet JL, Alessi MC, Morange PE, Collet JP, Montalescot G.

Am J Cardiol. 2013 Jan 1;111(1):38-44. doi: 10.1016/j.amjcard.2012.08.043. Epub 2012 Oct 2.

PMID:
23040597
2.

Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel.

Bonello L, Mancini J, Pansieri M, Maillard L, Rossi P, Collet F, Jouve B, Wittenberg O, Laine M, Michelet P, Bessereau J, Lemesle G, Dignat-George F, Paganelli F, Camoin-Jau L.

J Thromb Haemost. 2012 Oct;10(10):1999-2005. doi: 10.1111/j.1538-7836.2012.04875.x.

PMID:
22863374
3.

Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel.

Parodi G, Bellandi B, Venditti F, Carrabba N, Valenti R, Migliorini A, Grassellini S, Ramazzotti E, Antoniucci D.

Am J Cardiol. 2012 Jan 15;109(2):214-8. doi: 10.1016/j.amjcard.2011.08.034. Epub 2011 Oct 12.

PMID:
21996146
4.

Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.

Aradi D, Tornyos A, Pintér T, Vorobcsuk A, Kónyi A, Faluközy J, Veress G, Magyari B, Horváth IG, Komócsi A.

J Am Coll Cardiol. 2014 Mar 25;63(11):1061-70. doi: 10.1016/j.jacc.2013.12.023. Epub 2014 Jan 30.

5.

Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).

Cuisset T, Grosdidier C, Loundou AD, Quilici J, Loosveld M, Camoin L, Pankert M, Beguin S, Lambert M, Morange PE, Bonnet JL, Alessi MC.

JACC Cardiovasc Interv. 2013 Aug;6(8):854-63. doi: 10.1016/j.jcin.2013.04.009.

6.

Impact of obesity and the metabolic syndrome on response to clopidogrel or prasugrel and bleeding risk in patients treated after coronary stenting.

Pankert M, Quilici J, Loundou AD, Verdier V, Lambert M, Deharo P, Bonnet G, Gaborit B, Morange PE, Valéro R, Dutour A, Bonnet JL, Alessi MC, Cuisset T.

Am J Cardiol. 2014 Jan 1;113(1):54-9. doi: 10.1016/j.amjcard.2013.09.011. Epub 2013 Oct 4.

PMID:
24182762
7.

Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy.

Cuisset T, Gaborit B, Dubois N, Quilici J, Loosveld M, Beguin S, Loundou AD, Moro PJ, Morange PE, Alessi MC, Dutour A, Bonnet JL.

Int J Cardiol. 2013 Sep 20;168(1):523-8. doi: 10.1016/j.ijcard.2012.09.214. Epub 2012 Oct 16.

PMID:
23084816
8.

Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes.

Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, ten Berg JM, Miller DL, Costigan TM, Goedicke J, Silvain J, Angioli P, Legutko J, Niethammer M, Motovska Z, Jakubowski JA, Cayla G, Visconti LO, Vicaut E, Widimsky P; ACCOAST Investigators.

N Engl J Med. 2013 Sep 12;369(11):999-1010. doi: 10.1056/NEJMoa1308075. Epub 2013 Sep 1.

9.

Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]).

Damman P, Varenhorst C, Koul S, Eriksson P, Erlinge D, Lagerqvist B, James SK.

Am J Cardiol. 2014 Jan 1;113(1):64-9. doi: 10.1016/j.amjcard.2013.09.019. Epub 2013 Oct 3.

PMID:
24169009
10.

Safety and efficacy of prasugrel use in patients undergoing percutaneous coronary intervention and anticoagulated with bivalirudin.

Laynez A, Sardi G, Torguson R, Xue Z, Suddath WO, Satler LF, Kent KM, Pichard AD, Lindsay J, Waksman R.

Am J Cardiol. 2013 Feb 15;111(4):516-20. doi: 10.1016/j.amjcard.2012.10.035. Epub 2012 Dec 4.

PMID:
23219177
11.
12.

Nuisance and alarming bleeding do not correlate with on-treatment platelet reactivity.

Gaglia MA Jr, Torguson R, Pokharel S, Pakala R, Xue Z, Suddath WO, Kent KM, Satler LF, Pichard AD, Waksman R.

Cardiovasc Revasc Med. 2013 Mar-Apr;14(2):76-80. doi: 10.1016/j.carrev.2012.12.005. Epub 2013 Jan 31.

PMID:
23375617
13.

Ticagrelor vs prasugrel one-month maintenance therapy: impact on platelet reactivity and bleeding events.

Alexopoulos D, Stavrou K, Koniari I, Gkizas V, Perperis A, Kontoprias K, Vogiatzi C, Bampouri T, Xanthopoulou I.

Thromb Haemost. 2014 Sep 2;112(3):551-7. doi: 10.1160/TH14-02-0119. Epub 2014 Jul 3.

PMID:
24990396
14.

Switching acute coronary syndrome patients from prasugrel to clopidogrel.

Kerneis M, Silvain J, Abtan J, Cayla G, O'Connor SA, Barthélémy O, Vignalou JB, Beygui F, Brugier D, Martin R, Collet JP, Montalescot G.

JACC Cardiovasc Interv. 2013 Feb;6(2):158-65. doi: 10.1016/j.jcin.2012.09.012.

15.

Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.

Grosdidier C, Quilici J, Loosveld M, Camoin L, Moro PJ, Saut N, Gaborit B, Pankert M, Cohen W, Lambert M, Beguin S, Morange PE, Bonnet JL, Alessi MC, Cuisset T.

Am J Cardiol. 2013 Apr 1;111(7):985-90. doi: 10.1016/j.amjcard.2012.12.013. Epub 2013 Jan 19.

PMID:
23340030
16.

Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Loh JP, Pendyala LK, Kitabata H, Torguson R, Chen F, Kent KM, Satler LF, Suddath WO, Pichard AD, Waksman R.

Am J Cardiol. 2013 Mar 15;111(6):841-5. doi: 10.1016/j.amjcard.2012.11.058. Epub 2012 Dec 27.

PMID:
23273719
17.

Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.

Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlouros P, Hahalis G.

Circ Cardiovasc Interv. 2012 Dec;5(6):797-804. doi: 10.1161/CIRCINTERVENTIONS.112.972323. Epub 2012 Nov 20.

18.

Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial.

Erlinge D, Ten Berg J, Foley D, Angiolillo DJ, Wagner H, Brown PB, Zhou C, Luo J, Jakubowski JA, Moser B, Small DS, Bergmeijer T, James S, Winters KJ.

J Am Coll Cardiol. 2012 Nov 13;60(20):2032-40. doi: 10.1016/j.jacc.2012.08.964. Epub 2012 Oct 17.

19.

Incidence and outcome of high on-treatment platelet reactivity in patients with non-ST elevation acute coronary syndromes undergoing percutaneous coronary intervention (from the VIP [VerifyNow and Inhibition of Platelet Reactivity] study).

Saia F, Marino M, Campo G, Valgimigli M, Guastaroba P, Taglieri N, Tondi S, Manari A, Guiducci V, Sangiorgio P, Varani E, Magnavacchi P, De Palma R, Marzocchi A.

Am J Cardiol. 2013 Sep 15;112(6):792-8. doi: 10.1016/j.amjcard.2013.05.010. Epub 2013 Jun 5.

PMID:
23747044
20.

Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel.

Widimsky P, Motovska Z, Bolognese L, Dudek D, Hamm C, Tanguay JF, Ten Berg J, Brown E, LeNarz L, Miller DL, Montalescot G; ACCOAST Investigators.

Heart. 2015 Aug;101(15):1219-24. doi: 10.1136/heartjnl-2015-307686. Epub 2015 Jun 9.

PMID:
26060122
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk